ArticleCureus2026
Pseudo-autologous Stem Cell Transplant for the Treatment of Secondary Central Nervous System Lymphoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients who have previously undergone allogeneic stem cell transplantation and later have stem cells collected for an autologous transplant, the collected cells are sometimes referred to as "pseudo-autologous" to indicate that they are donor-derived. The use of pseudo-autologous stem cell transplantation (pASCT) has rarely been reported. We describe a case of pASCT in a 66-year-old man with multiple relapses of diffuse large B-cell lymphoma (DLBCL) despite prior chimeric antigen receptor T-cell (CAR T) therapy and a subsequent matched unrelated donor transplant. His most recent relapse after allogeneic transplantation was limited to the central nervous system (CNS) and presented with multiple cranial nerve palsies. Although previously collected autologous stem cells and donor-derived allogeneic stem cells were available, pseudo-autologous stem cells were collected during recovery from a modified salvage chemotherapy regimen (methotrexate (MTX), cytarabine, thiotepa, and rituximab (MATRix)). He subsequently received high-dose therapy with busulfan and thiotepa followed by pASCT. Despite receiving only brief (<1 month) graft-versus-host disease (GVHD) prophylaxis, he did not develop GVHD and remains disease-free 23 months after transplant. We discuss the rationale for selecting pASCT despite the availability of stored autologous and allogeneic stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.